NasdaqGS:INCYBiotechs
The Bull Case For Incyte (INCY) Could Change Following Raised 2025 Guidance and Oncology Program Updates – Learn Why
Incyte Corporation recently delivered strong third-quarter results and raised its full-year 2025 net product revenue guidance to a range of US$4.23 billion to US$4.32 billion, citing growth across its diversified product portfolio.
Alongside financial momentum, Incyte announced that key data from its oncology programs, including the first-in-class mutCALR therapy INCA033989, will be presented at the 2025 American Society of Hematology Annual Meeting, highlighting its pursuit of targeted...